Presentation is loading. Please wait.

Presentation is loading. Please wait.

7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.

Published byGerard Grant Modified over 8 years ago

Similar presentations

Presentation on theme: "7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA."— Presentation transcript:

1 7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA et al. JAMA 2005:293:1595-1608. ALLHAT

2 7/27/2006 Randomized Design of ALLHAT BP Trial 42,418 High-risk hypertensive patients Consent / Randomize AmlodipineChlorthalidoneDoxazosinLisinopril Follow until death or end of study (4-8 years, mean 4.9 years) ALLHAT

3 7/27/2006 ALLHAT reported no differences in the primary CHD outcome, but overall superiority of thiazide- type diuretic for first-step therapy of hypertension based on differences in secondary outcomes ALLHAT reported no differences in the primary CHD outcome, but overall superiority of thiazide- type diuretic for first-step therapy of hypertension based on differences in secondary outcomes The population of blacks with hypertension has the highest morbidity and mortality from hypertension of any population group in the U.S. The population of blacks with hypertension has the highest morbidity and mortality from hypertension of any population group in the U.S. Race was a prespecified subgroup for ALLHAT Race was a prespecified subgroup for ALLHAT Race Subgroup Analysis ALLHAT

4 7/27/2006 Baseline Characteristics by Race (Chlorthalidone, Amlodipine, Lisinopril) BlackNon-Black N11,79221,565 Age – mean (sd)66.3 (7.8)67.2 (7.6) Women (%)54.542.7 SBP – mean (sd)146.2 (15.8)146.3 (15.6) DBP – mean (sd)84.8 (10.2)83.6 (10.0) Current smokers (%)25.120.1 ASCVD (%)44.855.2 Diabetes Classification (%) Diabetes46.339.0 Impaired fasting glucose3.84.8 Normoglycemic49.956.2 LVH by ECG (%)23.912.3 HDL-C – mean (sd) mg/dl51.7 (15.6)44.3 (13.5) ALLHAT

5 7/27/2006 ChlorthalidoneAmlodipineLisinopril SBP – mean (sd) Black135.0 (15.8)136.1 (15.3)139.1 (19.7) Non- black 133.3 (14.8)133.8 (14.6)134.2 (16.7) DBP – mean (sd) Black77.4 (10.0)76.3 (10.1)78.0 (11.4) Non- black 74.4 (9.5)73.6 (9.6)74.1 (10.1) ∆ SBP/DBP compared with chlorthalidone Black---+1.1 / -0.7+5.2* / +1.4* Non- black ---+0.2 / -1.1*+0.5 / -0.5 Blood Pressure at 5 Years by Race * P < 0.005 compared to Chlorthalidone ALLHAT

6 7/27/2006 Black-ChlorBlack–AmlodBlack–Lisin Nonblack–ChlorNonblack–AmlodNonblack–Lisin BP Results by Treatment Group by Race ALLHAT

7 7/27/2006 % on 3+ Antihypertensive Drugs by Randomized Group and Race at 5 Years ALLHAT

8 7/27/2006 BP Control (<140/90 mm Hg) and Mean BP by Randomized Group and Race at 5 Years 135/78136/76139/79133/74 134/74 134/74 ALLHAT

9 7/27/2006 Serum Potassium (mean mmol/l) by Treatment Group and Race ChlorAmlodLisin BlackBaseline4.34.34.3 2 Years 4.04.34.4 4 Years 4.14.44.4 Non-BlackBaseline4.44.44.4 2 Years 4.14.44.5 4 Years 4.24.44.6 ALLHAT

10 7/27/2006 Serum Cholesterol (mean mg/dl) by Treatment Group and Race ChlorAmlodLisin BlackBaseline218218217 2 Years 209204204 4 Years 202199198 Non-BlackBaseline215216215 2 Years 204202201 4 Years 195194194 ALLHAT

11 7/27/2006 Fasting Glucose (mean mg/dl) by Treatment Group and Race ChlorAmlodLisin BlackBaseline127126127 2 Years130128124 4 Years130126125 Non-BlackBaseline122122121 2 Years126120119 4 Years125123120 ALLHAT

12 7/27/2006 Fasting Glucose  126 mg/dl by Treatment Group and Race ChlorAmlodLisin BlackBaseline31%32%31% 2 Years35%34%29% 4 Years34%33%28% Non-BlackBaseline28%28%28% 2 Years32%28%28% 4 Years32%30%29% ALLHAT

13 7/27/2006 Black vs. Non-Black Amlodipine/Chlorthalidone Relative Risk and 95% Confidence Intervals Nonfatal MI + CHD Death All-Cause Mortality Combined CHD Combined CVD Stroke End Stage Renal Disease Heart Failure Black Favors Amlodipine 0.50 12 1.46 (1.24 - 1.73) 1.15 (0.84 - 1.58) 0.93 (0.76 - 1.14) 1.06 (0.96 - 1.16) 1.03 (0.91 - 1.17) 0.97 (0.87 - 1.09) 1.01 (0.86 - 1.18) Favors Chlorthalidone Non-Black 0.50 12 1.32 (1.17 - 1.49) 1.08 (0.79 - 1.48) 0.93 (0.79 - 1.10) 1.04 (0.97 - 1.10) 0.99 (0.92 - 1.07) 0.94 (0.87 - 1.03) 0.97 (0.87 - 1.08) Favors Amlodipine Favors Chlorthalidon e ALLHAT

14 7/27/2006 ALLHAT Black vs. Non-Black Lisinopril/Chlorthalidone Relative Risk and 95% Confidence Intervals Nonfatal MI + CHD Death All-Cause Mortality Combined CHD Combined CVD Stroke End Stage Renal Disease Heart Failure Black Favors Lisinopril Favors Chlorthalidone Non-Black Favors Lisinopril Favors Chlorthalidone 0.5012 1.13 (1.00 - 1.28) 0.93 (0.67 - 1.30) 1.00 (0.85 - 1.17) 1.06 (1.00 - 1.13) 1.01 (0.93 - 1.09) 0.97 (0.89 - 1.06) 0.94 (0.85 - 1.05)

15 0 4 8 12 Cumulative HF Rate, % 0123456 Years to HF Chlorthalidone Amlodipine Lisinopril Heart Failure Rate for Blacks by Treatment Group No. at Risk Amlodipine321328792423720 Lisinopril321028372361711 Chlorthalidone5369483840411175 ALLHAT

16 0 4 8 12 Cumulative HF Rate, % 0123456 Years to HF Chlorthalidone Amlodipine Lisinopril Heart Failure Rate for Non-Blacks By Treatment Group No. at Risk Amlodipine5835530743741130 Lisinopril5844526243381132 Chlorthalidone9886906774791968 ALLHAT

17 7/27/2006 ANGIOEDEMA TotalBlacks Non- blacks Chlorthalidone8 / 15,255 0.1% 2 / 5,369 <0.1% 6 / 9,886 0.1% Lisinopril41 / 9,054 0.5% 23 / 3,210 0.7% 18 / 5,844 0.3% p<.001 p=.002 There were 3 cases (<0.1%) of angioedema in the amlodipine group (comparison to chlorthalidone not significant). ALLHAT

18 7/27/2006 Antihypertensive Trial: Implications Diuretics should be the drug of choice for initial therapy of hypertension. The evidence for this recommendation is even stronger for Black hypertensive patients.. For the patient who cannot take a diuretic (which should be an unusual circumstance), CCB’s and ACEI’s may be considered. However, in Black hypertensive patients, ACEI’s should be considered second-line therapy. Most hypertensive patients require more than one drug. Diuretics should generally be part of the antihypertensive regimen. Lifestyle advice should also be provided. ALLHAT

19 7/27/2006 Extra Slides

20 7/27/2006 Nonfatal MI + CHD Death1.01 (0.86 - 1.18) All-Cause Mortality0.97 (0.87 - 1.09) Combined CHD1.03 (0.91 - 1.17) Combined CVD1.06 (0.96 - 1.16) Stroke0.93 (0.76 - 1.14) Heart Failure1.46 (1.24 - 1.73) End Stage Renal Disease1.15 (0.84 - 1.58) Blacks Amlodipine/Chlorthalidone Relative Risk and 95% Confidence Intervals Favors Amlodipine Favors Chlorthalidone 0.5012 ALLHAT

21 7/27/2006 Nonfatal MI + CHD Death1.10 (0.94 - 1.28) All-Cause Mortality1.06 (0.95 - 1.18) Combined CHD1.15 (1.02 - 1.30) Combined CVD1.19 (1.09 - 1.30) Stroke1.40 (1.17 - 1.68) Heart Failure1.30 (1.10 - 1.54) End Stage Renal Disease1.29 (0.94 - 1.75) Blacks Lisinopril/Chlorthalidone Relative Risk and 95% Confidence Interval Favors Lisinopril Favors Chlorthalidone 0.5012 ALLHAT

22 7/27/2006 Nonfatal MI + CHD Death0.97 (0.87 - 1.08) All-Cause Mortality0.94 (0.87 - 1.03) Combined CHD0.99 (0.92 - 1.07) Combined CVD1.04 (0.97 - 1.10) Stroke0.93 (0.79 - 1.10) Heart Failure1.32 (1.17 - 1.49) End Stage Renal Disease1.08 (0.79 - 1.48) Non-Blacks Amlodipine/Chlorthalidone Relative Risk and 95% Confidence Intervals Favors Amlodipine Favors Chlorthalidone 0.501 2 ALLHAT

23 7/27/2006 Nonfatal MI + CHD Death 0.94 (0.85 - 1.05) All-Cause Mortality 0.97 (0.89 - 1.06) Combined CHD 1.01 (0.93 - 1.09) Combined CVD 1.06 (1.00 - 1.13) Stroke 1.00 (0.85 - 1.17) Heart Failure 1.13 (1.00 - 1.28) End Stage Renal Disease 0.93 (0.67 - 1.30) Non-Blacks Lisinopril/Chlorthalidone Relative Risk and 95% Confidence Intervals Favors Lisinopril Favors Chlorthalidone 0.50 1 2 ALLHAT

Download ppt "7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA."

Similar presentations

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in.
P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,

P Sever (Co-chair), B Dahlöf (Co-chair), N Poulter (Secretary), H Wedel (Statistician), G Beevers, M Caulfield, R Collins, SE Kjeldsen, A Kristinsson,
JNC 8 Guidelines….

JNC 8 Guidelines….
Www.allhatresearch.org ALLHAT New Research Opportunities.

ALLHAT New Research Opportunities.
11/2/2005 1 Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.

11/2/ Implications of ASCOT Results for ALLHAT Conclusions ALLHAT.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.

1 SECOND AUSTRALIAN NATIONAL BLOOD PRESSURE STUDY (ANBP-2) Enalapril/ACEI vs. HCTZ, n = 6,083 Randomized, open-label (blinded endpoint review) All CV events.
Valsartan Antihypertensive Long-Term Use Evaluation Results

Valsartan Antihypertensive Long-Term Use Evaluation Results
Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.

Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M.
Clinical Update on the JNC 7/8 Hypertension Guidelines

Clinical Update on the JNC 7/8 Hypertension Guidelines
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.

U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute The Antihypertensive and Lipid-Lowering.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.

1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.

Did Type of Prior Antihypertensive Therapy Influence the Heart Failure Results in ALLHAT? Richard Grimm, Barry Davis, Linda Piller, Karen Margolis, Joshua.
Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:2998-3007 ALLHAT- LLT.

Lipid Lowering Substudy Trial of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288: ALLHAT- LLT.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Slide Source: Lipids Online Slide Library www.lipidsonline.org Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)

Slide Source: Lipids Online Slide Library Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.

1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
6 / 5 / 2006 - 1 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
1 Setting the Record Straight ALLHAT. 2 Major ALLHAT Findings CHD risk not improved for any of the 3 newer agents compared with chlorthalidone Total mortality.

1 Setting the Record Straight ALLHAT. 2 Major ALLHAT Findings CHD risk not improved for any of the 3 newer agents compared with chlorthalidone Total mortality.

Similar presentations

Ads by Google